Abeona Therapeutics Inc Q1 2021 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Kristen Brianne Kluska - Cantor Fitzgerald & Co., Research Division - Analyst : This is Kristen Kluska of Cantor Fitzgerald. I wanted to ask a question on EB-101. So on the back of some of the recent data you shared at SID, how are you thinking about the durability of EB-101 across the different wound types evaluated? And how important do you think this durability data is going to be for physicians and a sales team to promote in choosing a potential treatment option, should multiple therapeutics become approved? And I know there's a lot of other factors to consider here like wound type and size, but I specifically wanted to hear your thoughts on durability.

Question: Kristen Brianne Kluska - Cantor Fitzgerald & Co., Research Division - Analyst : And I know you've discussed the key differences between the recur and chronic wounds, but I wanted to ask if your researchers and your team are doing some more work to better understand when the best time to intervene with this treatment might be for some of the recurrent wounds, excuse me, specifically, just in light of the fact that the different patterns in terms of time to healing, time to re-blistering, et cetera, just to help with the greatest chance of success if commercialized?

Question: Kristen Brianne Kluska - Cantor Fitzgerald & Co., Research Division - Analyst : Great. And then on your prepared remarks, you noted that some patients for the Phase III trial have been identified or in the prescreening process. Just wanted to make sure I understood that this was specifically referring to Stanford. And then I know you haven't identified the specific center in the Northeast, but could you talk about maybe more details? Like is this a center that you would expect a lot of patient interest? And have the investigators there potentially identified patients that they might want to go through the screening process? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. MAY 25, 2021 / 12:30PM, ABEO.OQ - Q1 2021 Abeona Therapeutics Inc Earnings Call